From standards of care to emerging treatment strategies, Ashish Kamat and Joshua Meeks discuss how clinicians approach non‑muscle‑invasive bladder cancer in real‑world practice today🎧

ow.ly/ZMqw50YH36B

#BladderCancer #MedicalEducation #Oncology

#ComingSoon in May, the launch of a new #BladderCancer campaign from @Tigerlily Foundation🌸 in collaboration with me, Dee Masters & Brittney Tellekamp! #YourStoryMatters #UrostomyLife #Advocacy
@tigerlilycares.bsky.social

ASCO_GU_ 2025_Social_Media_Report.pdf drive.google.com/file/d/1Q1DrPio5c6P4F3VeL-5b3UCSo7DR9hXm/view

🚀 Dive into #ASCOGU25 buzz!

Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.

#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺

Download our full report http://dlvr.it/TRxgfp !

#Oncology #SocialListening #LucidQuest

April Issue: Tumor Laterality Predicts Pelvic Lymph Node Metastasis Patterns in #BladderCancer

https://rdcu.be/fbDdB

A urine test that could change the course of bladder cancer care – BioNews Central A new study introduces a non-invasive urine test that can molecularly identify which bladder cancer patients benefit from additional therapy, allowing personalized treatment and avoiding unnecessary care. ...

A new study introduces a #noninvasive #UrineLiquidBiopsy that can molecularly identify which #BladderCancer patients benefit from additional #therapy, allowing #PersonalizedTreatment and avoiding unnecessary care. 
#BladderCancerTreatment

Coming in May for #BladderCancerAwarenessMonth a NEW Awareness Campaign I’m doing in collaboration with @Tigerlily Foundation🌸 , Brittney Tellekamp & Dee Masters! #AdvocacyLife #UrostomyLife #BladderCancer @tigerlilycares.bsky.social

Exciting news from Johnson & Johnson for #BladderCancer patients! CMS has now assigned a permanent billing code for their new bladder cancer treatment, #Inlexzo! This code will help make this treatment more accessible for those facing bladder cancer and their care teams!

Got to @tate #tatemodern for opening time to beat the crowds to see @traceyeminstudio exhibition #asecondlife. Really thought provoking multimedia art. The #stoma pictures following her #bladdercancer really resonated with me. That sense of not being whole & that vulnerability.

Exploring the Causal Role of IgG N-Glycosylation in Urological Cancers: A Two-Sample Mendelian Randomization Study Using European Ancestry Datasets Introduction: Urological cancers pose a significant global health burden. Alterations in immunoglobulin G(IgG) N-glycosylation are implicated in cancer pathogenesis, but their causal role remains unc...

#MendelianRandomization #ImmunoglobulinG #BladderCancer #ProstateCancer #UrologicalNeoplasms #KidneyCancer #Glycosylation

www.archivesofmedicalscience.com/Exploring-th...

#EchinocysticAcid inhibits #BladderCancer by inducing #ferroptosis and suppressing proliferation, invasion, and migration via AKT1/GSK3β/β‑catenin inhibition, synergizing with #gemcitabine as a safe therapeutic option.

#OpenAccess: doi.org/10.1016/j.ge...

We’re pleased to launch our new online support groups - a welcoming space for anyone affected by #bladdercancer to learn, share experiences & connect with others.

First session: Monday 11 May, 6:00-7:30pm
Topic: Staging & Grading

Read more here: actionbladdercanceruk.org/patient-even...

Exited & honored to share that I am part of a NEW #BladderCancerAwareness campaign that is launching next month in May, coinciding w/ #BladderCancerAwarenessMonth, in collaboration w/ Tigerlily! Stay tuned for more to come! #SomethingsComing #BladderCancer
@tigerlilycares.bsky.social

Anti-Inflammatory Diet Index (AIDI) and Bladder Cancer Risk by Stage: A 22-Year Prospective Swedish Cohort Study (1998–2020) Abstract. Background: Dietary patterns influencing systemic levels of inflammation have been proposed and investigated as possible determinants of cancer risk. We evaluated the association between the...

New in @theaacr.bsky.social: "In this large cohort with 22 years of follow-up, higher Anti-Inflammatory Diet Index scores were associated with lower bladder cancer risk, especially for muscle-invasive disease."🍒 #bladdercancer #oncology #cansky #oncsky #oncosky
aacrjournals.org/cebp/article...

🆕Our April issue is live!

📊Articles: #NSCLC, #bladdercancer, #melanoma, #prostatecancer, #breastcancer

📰Reviews: A PSOGI–ESGO–ISSPP Lyon consensus & OPTIMISE-AR recommendations for visualising PROs

Cover: Spaceflight as a cancer research catalyst

www.thelancet.com/issue/S1470-...

ASCO_GU_ 2025_Social_Media_Report.pdf drive.google.com/file/d/1Q1DrPio5c6P4F3VeL-5b3UCSo7DR9hXm/view

🚀 Dive into #ASCOGU25 buzz!

Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.

#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺

Download our full report http://dlvr.it/TRnBZB !

#Oncology #SocialListening #LucidQuest

New treatment reduces recurrence and improves survival in bladder cancer A combination of immunotherapy and targeted cancer treatment given before and after surgery may reduce the risk of recurrence and improve survival in patients with muscle‑invasive bladder cancer who cannot tolerate conventional chemotherapy. The findings come from a new study from Karolinska Institutet, published in The New England Journal of Medicine.

A new bladder cancer approach combining immunotherapy with targeted treatment shows reduced recurrence and improved survival. A promising step forward.
#BladderCancer #Immunotherapy #CancerResearch #TCSC
news.ki.se/new-treatmen...

#Exosomal lnc-TAF12–2:1 is upregulated in #BladderCancer, driving proliferation by sponging miR-7847–3p to stabilize ASB12; its inhibition suppresses #tumorigenesis, positioning it as a novel diagnostic and therapeutic #biomarker.

#OpenAccess: doi.org/10.1016/j.ge...

We invite submissions to the Special Collection Advances in Biomarkers for Genitourinary Cancers in Ther Adv Med Onc. We welcome studies on diagnostic, prognostic, predictive and molecular biomarkers across GU malignancies.
buff.ly/sQgaDWS
#GUcancer #Oncology #ProstateCancer #BladderCancer

We are supporting an important research study led by Birkbeck College, University of London. Researchers are looking to better understand people’s experiences of being diagnosed & treated for cancer.

Prof Anne Miles: ae.miles@bbk.ac.uk
Dr Claudia Redeker: claudia.redeker@bbk.ac.uk

#bladdercancer

Yale Launches Innovative Clinical Trial for Metastatic Bladder Cancer Yale researchers have launched an innovative study combining targeted therapy with surgery—an approach that would have been unthinkable just a few years ago.

Yale has launched an innovative trial for metastatic bladder cancer that brings surgeons, medical #oncologists and radiation specialists into one team, rather than treating each step in a silo. #BladderCancer #ClinicalTrials #TCSC
medicine.yale.edu/news-article...

Trial Tuesday! Dr. Matt Galsky of Mount Sinai Division of Gastroenterology leads Alliance A032103/MODERN trial investigating if DNA released from tumor cells into the blood helps identify the best #immunotherapy treatment after surgery for #bladdercancer. More info: https://bit.ly/Alliance-A032103

🚨 Call for Papers!
Our new Special Collection in Ther Adv Med Onc - Advances in Biomarkers for Genitourinary Cancers - is now open.
🗓 Deadline: 6 Nov 2026
🔗 Submit here: buff.ly/sQgaDWS
#Oncology #GUcancer #Biomarkers #ProstateCancer #BladderCancer #KidneyCancer

Why smoking is the top cause of bladder cancer Bladder cancer and smoking are strongly linked. Discover how tobacco toxins affect the bladder and why quitting improves survival and lowers recurrence.

“About 10 years after quitting, the risk of developing #BladderCancer is reduced by up to 50 percent. After 20-25 years, the risk approaches that of people who never smoked.”: buff.ly/iNF2Prb

from kevinmd
#smoking #cancer #smokers #cigarettes

Now enrolling! BCG (a bladder immunotherapy) is standard for non-muscle invasive bladder cancer. For cancer returned after BCG, the Alliance A032103 (GAIN) trial tests adding gemcitabine—a chemo drug—to BCG to prevent recurrence. Learn more: https://bit.ly/Alliance-GAIN-BCG #BladderCancer

🗣️ #Wolverhampton Patient Support Meeting - March 30th 🗣️

If you’re affected by #bladdercancer join us on March 30th for an informative talk on Cancer Complementary Services and Support by the Complementary Therapy Team.

⏰ 1.30pm til 3.30pm
📍 The Hub, WV11 2LH

#CancerSupport #PatientSupport

Neoadjuvant Mitomycin C Before TURBT May Cut NMIBC Recurrence, Progression Risks - Oncology Nurse Advisor A phase 2 trial evaluated the effectiveness and safety of neoadjuvant intravesical mitomycin-C instillation in patients with urothelial non-muscle invasive bladder cancer.

In #NMIBC, immediate administration of 2 doses of neoadjuvant intravesical mitomycin C chemotherapy prior to TURBT may reduce recurrence and progression risks compared with TURBT alone. From @renalurologynews.bsky.social.

https://bit.ly/41gINY2

#blcsm #bladdercancer

ASCO_GU_ 2025_Social_Media_Report.pdf drive.google.com/file/d/1Q1DrPio5c6P4F3VeL-5b3UCSo7DR9hXm/view

🚀 Dive into #ASCOGU25 buzz!

Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.

#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺

Download our full report http://dlvr.it/TRcw4G !

#Oncology #SocialListening #LucidQuest

Nadofaragene Firadenovec Is Added to NCCN Guidelines in BCG-Unresponsive Papillary NMIBC Without CIS | OncLive Nadofaragene firadenovec has been added to the NCCN guidelines in BCG-unresponsive papillary NMIBC without CIS.

The NCCN guidelines have now added nadofaragene firadenovec-vncg (Adstiladrin) as a category 2A recommendation for patients with BCG-unresponsive NMIBC with papillary Ta/T1 tumors without concomitant carcinoma in situ. #BladderCancer #NMIBC #oncology
🔗 Read more: www.onclive.com/view/nadofar...

New potential therapy developed in response to bladder cancer Adding an anti-inflammatory medication to immunotherapy and chemotherapy drugs may provide long-term suppression of bladder tumour growth.

Researchers have identified inflammatory signals that help bladder tumours hide from the immune system, opening the door to new combinations that may boost chemo‑immunotherapy. #BladderCancer #Immunotherapy #TCSC
www.drugtargetreview.com/news/102211/...

EA8231 Research Study for Patients With Advanced Urothelial Cancer Study chair Dr. Monika Joshi and co-chair Dr. Petros Grivas discuss this trial that aims to improve outcomes for patients with anti-PD(L)1-resistant advanced urothelial cancer.

New video: Dr. Monika Joshi & @pgrivasmdphd.bsky.social discuss the EA8231 #ClinicalTrial, which aims to evaluate and answer the critical question of #immunotherapy (anti-PD1/L1) rechallenge in #UrothelialCancer therapy. Watch here: bit.ly/47UxFnr #BladderCancer